40 results about "Bone marrow cell" patented technology

The invention discloses a kit and method for detecting leukemia and lymphoma based on full-spectrum flow cytometry, the kit comprises 25 antibodies, the antibodies are specifically bound with fluorescein respectively, and leukemia and lymphoma are detected through full-spectrum flow cytometry; the 25 kinds of antibodies comprise HLA-DR (human leukocyte antigen-DR), CD38, CD7, CD34, Lambda, CD19, CD64, CD14, CD5, CD123, CD16, CD20, Kappa, CD117, CD13, CD45, CD11b, CD2, CD10, CD8, CD15, CD4, CD3, CD56 and CD33. The kit comprehensively covers development stages of various lines of bone marrow cells, and common abnormal expressions of various leukemia, myelodysplastic syndromes and lymphoma, and can preliminarily screen various leukemia and lymphoma.

Methods, systems, and compositions are provided for extracting bone marrow cells from bone obtained from deceased donors, for preparing the bone marrow for cryopreservation, and for obtaining desired cells from cryopreserved and fresh bone marrow

The application discloses a method for establishing a mouse model of MHC haplotype compatible allogeneic hematopoietic cell transplantation, and belongs to the technical field of animal experiment model construction. The technical problem to be solved by the application is how to construct a mouse model which can be used to study the immune reconstruction mechanism and treatment effect evaluation of MHC haplotype compatibility and MHC full compatibility in bone marrow cell transplantation recipient mice. To solve the technical problem, the application provides a method for constructing a mouse model of MHC haplotype compatible allogeneic hematopoietic cell transplantation, which comprises transplanting bone marrow cells of a donor mouse into a recipient mouse, and the MHC haplotype of the donor mouse and the recipient mouse is compatible. The application sets a modeling condition, and the model establishment condition is evaluated by survival condition, graft-versus-host disease and rejection reaction observation, flow cytometry and histopathological section, so as to prove that the model is reliable and stable.

The invention belongs to the field of immunotoxicology, and particularly relates to a method for immunotyping bone marrow cells by flow cytometry. The flow cytometry immune typing method for bone marrow cells comprises the following steps: collecting macaca fascicularis bone marrow fluid, and preparing the macaca fascicularis bone marrow fluid into single-cell suspension; dyeing the obtained cells by using an antibody combination containing a plurality of fluorescent labels; then, a flow cytometer is used for collecting cell fluorescence signals, a standardized gate setting strategy is executed, and based on collected data, the percentage of each cell subset in CD45 + living white blood cells is calculated to complete immune typing. According to the flow cytometry immune typing method for the bone marrow cells, the problems of low efficiency, low repeatability, low sensitivity and poor specificity of related technologies are solved, and more accurate and reliable data support is provided for early discovery, risk assessment and mechanism research of drug immunotoxicity.

The present invention relates to a computer-implemented method for producing a trained model for detecting one or more defined cell types and / or cellular indicators, such as biomarkers or cellular abnormalities, in particular genomic aberrations, from single-cell images obtained from a sample of a body liquid, bone marrow, cytology smear or slide preparations, in particular a blood smear sample. It relates also to a computer-implemented method for detecting one or more defined cell types and / or cellular indicators, such as biomarkers or cellular abnormalities, in particular genomic aberrations, from single-cell images obtained from a sample of a body liquid, bone marrow or cytology smear, in particular a blood smear sample.

The present invention relates to a method of identifying rejuvenating factor(s) by culturing bone marrow cells wherein age-specific human serum is added to the bone marrow cells and to a method of testing active agents to augment the effect of the one or more rejuvenating factor(s) identified.

The bone marrow cell morphology analysis system provided by this invention includes a base, a feeding module mounted on the base, and a detection module mounted on the base to one side of the feeding module. The feeding module includes a slide holder and a slide conveying mechanism, and the detection module includes a microscope and a slide placement platform. The slide conveying mechanism can automatically transport slides from the slide holder to the slide placement platform located below the microscope. After the sample on the slide is detected by the microscope, the slide conveying mechanism automatically returns the slide to the slide holder. The entire process can achieve fully automated operation, which not only greatly improves the efficiency of sample detection, but also helps to ensure the accuracy of each test result because it uses mechanical operation.

The present application relates to the technical field of traditional Chinese medicine, in particular to a traditional Chinese medicine composition for reducing adverse reactions after radiotherapy and chemotherapy of tumor patients and a preparation method thereof, comprising the following components in parts by weight: Radix Bupleuri 6-9 parts, Radix Paeoniae Alba 6-9 parts, Rhizoma Atractylodis Macrocephalae 6-9 parts, Poria 6-9 parts, Angelica sinensis 6-9 parts, Zingiber officinale 3 parts, Radix Rehmanniae Recens 3-6 parts, Gardenia 3-6 parts, Radix Paeoniae Rubra 3-6 parts, Radix Paeoniae Alba 12-20 parts, Rhizoma Chuanxiong 6 parts, and Radix Glycyrrhizae 3-6 parts; the traditional Chinese medicine composition can improve the spirit and movement state of mice, and the weight and food intake of mice are obviously increased, the number of dead mice is significantly reduced, and the tumor volume and weight of mice are significantly reduced; the spleen and thymus indexes, the number of white blood cells, red blood cells and platelets in peripheral blood, and the hemoglobin content are all significantly increased; the number of bone marrow cells and the CD4 + T / CD8 + T cell ratio in peripheral blood are all significantly increased; when applied to clinical patients, the traditional Chinese medicine composition can reduce adverse reactions after radiotherapy and chemotherapy of tumor patients, and has a broad application prospect.

The application discloses a bone marrow morphology acute event identification early warning system and relates to the technical field of intelligent medical treatment, and the technical solution points are as follows: acquiring bone marrow cell image data, pre-processing, obtaining pre-processed image data; inputting the pre-processed image data into a trained AI model, and outputting a classification prediction result. The application can more accurately identify and classify bone marrow cells by applying a visual Transformer and a visual Mamba model, can identify different cell development stages, and can diagnose various blood diseases through an AI model standardized analysis process, reduce professional barriers in the field of bone marrow morphology, reduce absolute dependence on expert experience, and enable areas with insufficient medical conditions to also obtain high-quality preliminary diagnosis.

Fibrinogen-coated Albumin Nanospheres (FAS) has shown that it can mobilize bone marrow cells into the blood which then go to injured soft and hard tissues to achieve accelerated repair. It is hypothesize that (a) brain injuries caused by low-dose irradiation under simulated microgravity can be mitigated by the administration of FAS; and (b) the mechanism is from acceleration of neo-vascularization, proven by lineage study of GFP-labeled bone marrow cells implanted into compatible non-GFP animals before injury, which regenerate into functional GFP-brain cells after FAS treatment.

Provided are methods and compositions conditioning a patient for an allogeneic transplantation, wherein the patient's hematopoietic stem cells (HSCs) are depleted with an HSC-depleting composition and the patient is then administered allogeneic cells selected from bone marrow cells, umbilical cord blood cells, hematopoietic stem and progenitor cells (HSPCs), peripheral blood CD34+ cells, and peripheral blood CD34+ and CD90+ cells; optionally the patient is also administered a medicament selected from the group consisting of a T-cell depleting or inhibiting antibody or antibody fragment, NK-cell depleting or inhibiting antibody or antibody fragment, immunosuppressive drug, and any combination thereof. The HSC-depleting composition comprises a compound selected from the group consisting of: an antibody or antibody fragment with specific binding affinity to a protein displayed at the HSC surface, a conjugate comprising an HSC-recognition molecule and a toxin, and any combination thereof.

The present invention relates to engineered SIRP alpha variants and methods of use thereof. Signal regulatory protein a (SIRPa) is a regulatory membrane glycoprotein of the SIRP family. The protein is mainly expressed by bone marrow cells and also expressed by stem cells or neurons. SIRPa is used as an inhibitory receptor and interacts with a widely expressed transmembrane protein CD47. The present disclosure relates to engineered SIRPa variants and methods of use thereof.

The invention relates to the crossing field of medical image processing and artificial intelligence technology, in particular to a bone marrow cell morphology artificial intelligence analysis method and system, and the method comprises the steps: obtaining a multi-view high-resolution image of a bone marrow smear and / or a peripheral blood smear under the oil immersion magnification, and carrying out the preprocessing; carrying out red blood cell coarse segmentation and fine classification through a cascade deep network, and identifying target-shaped, broken, teardrop-shaped and elliptical red blood cells; correcting broken red blood cell counting by adopting a fragment aggregation correction algorithm; and calculating an MCI value in combination with blood routine test data, and carrying out weighted fusion on the MCI value and the abnormal red blood cell proportion to generate a thalassemia screening comprehensive score. Therefore, the problems of low manual identification efficiency, insufficient abnormal red blood cell identification accuracy, large broken red blood cell counting deviation, difficulty in distinguishing multiple types of abnormal red blood cells, lack of organic combination with clinical diagnosis indexes and the like are solved, and the efficiency and accuracy of morphological analysis of bone marrow cells are improved; and a reliable basis is provided for diagnosis of diseases such as thalassemia.

The present invention relates to a computer-implemented method for producing a trained model for detecting one or more defined cell types and / or cellular indicators, such as biomarkers or cellular abnormalities, in particular genomic aberrations, from single-cell images obtained from a sample of a body liquid, bone marrow, cytology smear or slide preparations, in particular a blood smear sample. It relates also to a computer-implemented method for classifying a sample of a body liquid, bone marrow or cytology smear, in particular a blood smear sample, as indicative or non-indicative of one or more defined cell types and / or cellular indicators, such as biomarkers or cellular abnormalities, in particular genomic aberrations, from single-cell images obtained from the sample.

The invention relates to a method for regulating osteogenic differentiation of periodontal ligament stem cells in an inflammatory microenvironment based on a stem cell-derived extracellular matrix. The method comprises the following steps: 1) separating and identifying bone marrow cells BMCs and periodontal ligament cells PDLCs; (2) preparing a bone marrow stem cell derived extracellular matrix B-ECM and a periodontal ligament stem cell derived extracellular matrix P-ECM; 3) intervening PDLSCs in an inflammation microenvironment by using the B-ECM and the P-ECM obtained in the step 2), and 4) performing animal experiment.The adverse effect of inflammation on the osteogenic differentiation capacity of periodontal ligament stem cells in the stem cell treatment process is reversed, so that a basis is provided for developing a novel periodontitis regeneration treatment strategy based on an ECM stent.

The invention belongs to the field of biological medicines, and particularly relates to application of medicarpin in preparation of medicines for preventing and / or treating immunosuppressive diseases. According to the application disclosed by the invention, it is found that the mendalin can increase the content of IL-3 and M-CSF in serum, reduce the content of EPO and increase the content of IL-34 and IL-15 in bone marrow at the same time; and the red sandalwood can increase the number of leukocytes, platelets and basophilic granulocytes in peripheral blood and enhance the multiplication capacity of bone marrow cells, so that the red sandalwood can be used for preventing and / or treating the immunosuppressive diseases, and is further used for preparing the medicines for preventing and / or treating the immunosuppressive diseases.

The application discloses a mouse bone marrow mesenchymal stem cell separation method, which comprises the following steps: S1, extracting mouse bone marrow cells; S2, performing flow staining, specifically comprising the following sub-steps: resuspending the mouse bone marrow cells by using Hanks buffer solution containing FBS to obtain a mouse bone marrow cell suspension, performing specific blocking treatment on the mouse bone marrow cell suspension, adding a fluorescently labeled monoclonal antibody to the mouse bone marrow cell suspension after centrifugation, washing and resuspension, and incubating to obtain the flow-stained mouse bone marrow cells; the fluorescently labeled monoclonal antibody comprises Anti-CD140a-APC, Anti-CD45-PE, Anti-Sca-1-FITC and Anti-Ter119-PE; S3, performing flow sorting on the flow-stained mouse bone marrow cells, sorting PE ‑ , FITC + , APC + cell groups by using a flow cytometer to obtain mouse bone marrow mesenchymal stem cells. The application can more efficiently and stably separate mouse bone marrow mesenchymal stem cells.

The invention provides a preparation method of an experimental animal bone marrow smear, and belongs to the technical field of hematological examination. According to the invention, a specific smear method is matched with homologous serum, so that the mechanical damage of bone marrow cells in the collection and smear preparation process can be obviously reduced, and the phenomena of excessive crushing and uneven distribution of the cells are effectively avoided, so that the high-quality bone marrow smear with complete cell morphology and clear background is prepared; therefore, the morphological observation effect and the reading success rate of the bone marrow cells are directly improved, reliable technical guarantee is provided for accurately evaluating the influence of the test substance on the hematopoietic function of the animal in non-clinical toxicity research, and the accuracy and repeatability of experimental results are enhanced.

The invention discloses a traditional Chinese medicine hemagglutination rehabilitation composition for treating aplastic anemia and a preparation method thereof, and is characterized in that the traditional Chinese medicine hemagglutination rehabilitation composition is synthesized from extracts of morinda officinalis, angelica sinensis, American ginseng, rhizoma polygonati, astragalus membranaceus, cistanche, mulberry, raspberry, fructus alpiniae oxyphyllae, hawthorn, Chinese yam, fructus perillae, jujube, semen cassiae and cordyceps sinensis. Compared with the prior art, the traditional Chinese medicine composition for treating aplastic anemia disclosed by the invention has the advantages that a compound compound of a traditional Chinese medicine extract enters blood cells of a human body, mitochondria in the cells converts the compound into ATP (adenosine triphosphate) to supply energy of cell nucleuses (gene DNA), and the cell nucleuses start to split and start and stimulate bone marrow cell regeneration; the traditional Chinese medicine composition can be used for activating body dormant cells, supplementing hemoglobin and recombining stem cells, providing new blood after cell recombination for human body functions, and restarting a basic hematopoietic function of bone marrow, so that the aim of treating aplastic anemia is fulfilled.

Using an aldehyde dehydrogenase-1A enzyme inhibitor (ALDHi) for expanding bone marrow cells and / or dendritic cells and for adjuvant therapy to an immunotherapy

The invention belongs to the technical field of medicines, and particularly relates to application of benzyl selenenitrile in preparation of a medicine for preventing and / or treating pancreatic cancer. The benzylselenenitrile can effectively inhibit in-vivo growth of pancreatic cancer by improving immune cell infiltration in a pancreatic cancer tumor microenvironment and a killing function of anti-tumor cells such as CD8 + T cells, so that the effect of preventing and / or treating the pancreatic cancer is achieved. Experimental results show that the structures of the liver, spleen, kidney and lung of the mouse subjected to BSC intraperitoneal injection treatment have no significant difference from those of a control mouse, and the proliferation capacity of bone marrow cells also has no significant difference, so that the BSC does not generate visceral organ and bone marrow toxicity.

This invention discloses a method for identifying bone marrow cells from microscopic images based on feature fusion, comprising: acquiring labeled microscopic images of bone marrow cells to construct a dataset, dividing it into a training set and a test set; performing data augmentation on the images in the training set to obtain an augmented training set; feeding the augmented training set into an improved Mask R-CNN network for training to obtain an optimal model; inputting the test set into the optimal model to obtain prediction information, including: the location bounding box, category, and segmentation mask information of each bone marrow cell; drawing this information onto the original image; and marking the predicted bone marrow cell category above the location bounding box, thereby completing the identification of bone marrow cells. This invention improves the generalization of bone marrow cell image recognition across various color styles.

The invention relates to the field of neurology, neurobiology, and neurological disorders. The invention relates to a pharmaceutical combination comprising a colony-stimulating factor 1 receptor (CSFR1R) inhibitor and a bone marrow cell population for use in the treatment of central nervous system (CNS) diseases. The invention further relates to an ex vivo method for depleting dysfunctional and / or mutant microglia and / or CNS-associated macrophages (CAM), the method comprising providing a population of cells comprising myeloid cells and treating said cells with an CSF1R inhibitor of central nervous system (CNS)-associated myeloid cells, thereby depleting dysfunctional and / or mutant microglia. The invention relates to a cell population according to the ex vivo method. The invention further relates to a pharmaceutical composition comprising the CSF1R inhibitor according to the present invention for use in the treatment or prevention of a medical condition induced by dysfunction of immune cells in a central nervous system (CNS), additionally comprising a pharmaceutically acceptable carrier.

The application provides a method for automatically segmenting white blood cells in bone marrow cells, comprising the following steps: S1, extracting obvious cells CellGray from an input bone marrow cell rgb image through a convolutional neural network; S2, binarizing the bone marrow cell image CellGray to obtain a white blood cell nucleus binary image; S3, performing an opening and closing operation on the white blood cell nucleus binary image in the aspect of image morphology to obtain WhiteCellMorph, and performing a watershed algorithm operation on WhiteCellMorph to obtain a white blood cell nucleus segmentation image Leukocytenucleus; S4, shielding corresponding numbers in the CellGray data obtained in step S1 by using the Leukocytenucleus obtained in step S3, and obtaining a white blood cell membrane Leukocytemembrane by using an Otsu method and an opening and closing operation in the aspect of image morphology; and S5, combining the data obtained in steps S3 and S4 to obtain a segmented complete white blood cell image, extracting an accurate position of the white blood cell, and generating a standard data set. The application can effectively improve the accuracy of overall positioning and segmentation of white blood cell images, and generate a data set, thereby facilitating the development of artificial intelligence for subsequent white blood cell type recognition.

The invention provides a construction method and application of an osteoporosis mouse model, and the method comprises the following steps: taking a female mouse as a donor, carrying out bilateral ovariectomy, after feeding for 5-12 weeks after the operation, separating bone marrow cells of thighbone and tibia, and carrying out flow cytometry to obtain bone marrow mesenchymal stem cells and macrophages; the method comprises the following steps: taking a male mouse as a receptor, performing irradiation to remove self bone marrow cells, transplanting bone marrow mesenchymal stem cells and macrophages of an ovarian group donor through caudal vein within 24 hours, and feeding for 1.5-4 months after transplanting to obtain the osteoporosis mouse model. The osteoporosis mouse model can be used for preparing targeted drugs related to bone metabolism, especially drugs for preventing and / or treating osteoporosis.

A non-invasive method for detecting bone marrow pathology is provided, comprising receiving a metacell model of multiple metacell types based on single-cell RNA sequencing (scRNA-seq) of CD34-positive cells from peripheral blood and comparing it to a control value of CD34-positive cell metacells from peripheral blood of a healthy subject. A non-invasive method for predicting the percentage of blast cells in the bone marrow and calculating an IPSS-M risk score is also provided, as well as a system for carrying out the method of the present invention.

The invention discloses humanized lactobacillus johnsonii MYR-117 and application thereof, the preservation number of the humanized lactobacillus johnsonii MYR-117 is GDMCC No: 65346, the humanized lactobacillus johnsonii MYR-117 is separated and identified from a faeces sample of a healthy person, and a mouse myelosuppression model is further combined to find that the lactobacillus johnsonii can resist myelosuppression induced by cyclophosphamide, so that the lactobacillus johnsonii MYR-117 can be used for resisting myelosuppression induced by cyclophosphamide; the levels of white blood cells, hemoglobin, platelets and red blood cells can be increased, bone marrow cell apoptosis is reduced, the thighbone marrow form is recovered, and the bone marrow hematopoietic capacity is Therefore, the compound can be used for preparing anti-myelosuppression drugs, leukocyte increasing drugs, erythrocyte increasing drugs, chemotherapy adjuvant therapy drugs and health-care products. Meanwhile, as the lactobacillus johnsonii is edible probiotics, the lactobacillus johnsonii can be used for preparing health-care food.

The invention belongs to the technical field of biology, and discloses application of arginine in preparation of a kit for recovering NK cell functions and treating leukemia. The invention has the following beneficial effects: the inventor reports the application of supplementing arginine in the NK cells for treating acute myelogenous leukemia for the first time. Experimental results show that the ability of damaged bone marrow NK cells of AML patients to kill tumor cells can be recovered by supplementing arginine, and results of in-vivo experiments further show that the survival time of acute myelogenous leukemia model mice can be prolonged by recovering NK cell treatment cultured by arginine, and leukemia cell load is inhibited. Therefore, a certain experimental basis is provided for clinically treating the recurrent and refractory AML by using the arginine.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a composition for repairing immune injury and a preparation method and application thereof. The invention provides a composition for repairing immune injury. The composition comprises the following raw materials in parts by weight: 10-20 parts of astragalus membranaceus, 1-4 parts of schisandra chinensis, 2-6 parts of ginseng, 2-6 parts of radix ophiopogonis, 2-6 parts of pericarpium citri reticulatae, 2-6 parts of semen armeniacae amarae and 2-6 parts of angelica sinensis. The composition promotes immune recovery of mice with immune injury after chemotherapy and recovers the number of immune cells and bone marrow cells, so that the composition can be used for repairing immune injury caused by chemotherapy, and has good prospects in the aspects of preparation of drugs for regulating immunity or repairing immune injury and preparation of health-care foods beneficial to enhancing immunity.

Described herein, in part, are bisphosphonate lipid compounds, lipid nanoparticles (LNPs) thereof, and methods of use thereof. In various embodiments, the LNP selectively targets a cell of interest (e.g., a bone cell and / or bone marrow cell, such as a stem cell, stroma cell, osteoblast, osteocyte, osteoclast, bone lining cell, local mesenchymal cell, progenitor cell, mononuclear blood-borne precursor cell, B cell, endothelial cell, granulocytes, T cell, monocytic lineage, B cell lineage, monocytes, cancer cell, tumor cell, tumor cell that metastasize to bone, blood cancer cell, and multiple myeloma cell, inter alia). In other aspects, the present disclosure relates to methods for in vivo delivery of therapeutic agents to prevent or treat diseases, disorders, or conditions using the LNP compositions of the disclosure.